MD Anderson's Therapeutics Discovery division, Orionis Biosciences launch Project Helios to advance novel small-molecule cancer medicines

(University of Texas M. D. Anderson Cancer Center) MD Anderson's Therapeutics Discovery division and Orionis Biosciences today announced the launch of Project Helios, a new collaboration designed to unlock new drug development opportunities through genome-scale mapping of drug-target interactions.